Sylvant (siltuximab) / BeOne Medicines, Jazz - LARVOL DELTA

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data (ASH 2025) - P | "Prior immunotherapies included: HSCT(21.4%), inotuzumab ozogamicin (18.6%), and blinatumomab (28.3%)...All patients recovered without sequelae, with 38 treatedwith corticosteroids, and 33 with tocilizumab or siltuximab.Real-world data on Inati-cel corroborates its robust response rate, favorable toxicity profile, and survivalbenefits. Real-world data on Inati-cel corroborates its robust response rate, favorable toxicity profile, and survivalbenefits. Inati-cel demonstrates efficacy in patients with active extramedullary diseases, particularlythose with CNSL. In vivo expansion was observed across different disease states."

Clinical • IO biomarker • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • CD4 • CD8 • IKZF1 • KMT2A • PAX5 • TP53

A rubric‑based comparison of code red and specialists in managing CAR‑T–Related cytokine release syndrome and icans (ASH 2025) - "Its margin was driven by a consistently protocol-level presentation—explicit monitoring schedules, predefined intervention thresholds (e.g., tocilizumab at 24 h of persistent fever), steroid regimens, ICU escalation criteria, and tertiary options (anakinra/siltuximab)—delivered in concise, highly actionable language. Conclusions A lean, expert-guided RAG system (Code Red) can outperform individual CAR-T specialists on simulated toxicity management scenarios while delivering rapid guidance. Ongoing improvement will rely on continuous user feedback and automated literature surveillance to preserve patient safety and guideline fidelity."

Cytokine release syndrome • Inflammation

Clinical features of castleman disease: Single institution experience (ASH 2025) - "Treatment varied in this group including rituximab, siltuximab, and tocilizumab. This investigation highlights the importance of accurate classification and comprehensive diagnostic evaluation in CD. While limited by sample size and single-institution design, this study contributes to the growing body of literature on this rare disease and emphasizes the need for ongoing research into its pathophysiology, optimal management, and long-term outcomes."

Clinical • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Rare Diseases • Sarcoma • Solid Tumor

Comparable response rates to therapies in idiopathic multicentric castleman disease patients with and without expert-confirmed diagnoses (ASH 2025) - "Clinical response rates for siltuximab±CS were 66% (29/44) vs 76% (45/59); chemotherapy 61% (11/18) vs 82% (27/33); tocilizumab±CS 67% (4/6) vs 57% (12/21); and anti-IL6+immunomodulators±CS 67% (6/9) vs 67% (10/15), respectively (all n.s.). While these findings suggest that patients with iMCD-like features may respond to iMCD therapies and demonstrate how other lymphoproliferative and inflammatory diseases may share targetable pathophysiological features, this is not intended to recommend anti-IL6 therapy without iMCD diagnosis. Limitations of the registry analysis include small sample size, missing data, and the absence of randomization, which may impact interpretation of results."

Clinical • Hematological Malignancies • Immunology • Rare Diseases

First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study. (ASH 2025) - P1 | "Siltux was administered at day (d) 8 after the end of a standard AML induction chemotherapy (IVidarubicine 8 mg/m2 d1 to d5 + IV cytarabine 100 mg/m2 d1 to d7)...Among the 10 ND AML pts, all were classified as adverse-risk (ELN-2022classification), 6 had complex karyotype and 6 had secondary AML, including 2 who had been alreadytreated for myelodysplastic syndrome (azacitidine and upfront allo-HCT). One R/R AML had received low-dose aracytine + venetoclax in first line and had a normal karyotype with RUNX1 mutation at relapse... This phase 1 first-in-human study showed that the addition of Siltux at d8 of a standard AMLintensive induction is safe and provides relatively good response rate in a very high-risk AML population.We now recommend a dose of 11 mg/kg of Siltux given at d8 of intensive AML induction for further phase2/3 studies."

Clinical • Combination therapy • First-in-human • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Rare Diseases • Septic Shock • FLT3 • KMT2A • RUNX1

Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices (ASH 2025) - "Ptsreceived the following CRS/ICANS treatment(s) across diseases: tocilizumab (64%-82%),dexamethasone (40%-89%), anakinra (5.5%-22%), methylprednisolone (1.9%-14%),siltuximab (0.9%-4.1%).Hospitalization rate after CAR T was 51% of DLBCL, 69% of MCL, 56% of MM. In this rw study of over 2,500 pts with DLBCL, MCL, and MM treated with CAR T, theprevalence and severity of CRS/ICANS were generally consistent with clinical trials, with a notable declinein grade >3 events over time in DLCBL. Majority of pts were treated in the inpatient setting and atacademic centers, though a meaningful proportion received CAR T in the outpatient setting (8-18%) or atcommunity practices (5-13%), reflecting increased diversity in care delivery. Across disease cohorts, ptswith grade >3 CRS had more than double ICU-level care compared to pts with lower-grade events,reflecting the substantial HCRU burden associated with severe toxicities."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Reimbursement • US reimbursement • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Torque teno virus in pediatric CAR-T recipients (ASH 2025) - "Cytokine release syndrome (CRS) occurred in 85.2% patients (median 3 days, [1,6.5]), ICANS in 29.6%(mean 8.13 days, SD 2.6), and hemophagocytic lymphohistiocytosis (HLH) in 37% (mean 8 days, SD 2.6).Tocilizumab was administered in 40.7%, siltuximab in 29.6%, steroids in 48.1%, and anakinra in 33.3%cases. We found no associations with CARTflow subsets. CONCLUSIONSIn pediatric CART recipients, TTV-VL does not correlate with CART monitoring methods, but could predicttoxicity and outcomes."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Developmental Disorders • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pediatrics • Rare Diseases

Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome (ASH 2025) - P2 | "These findings, along with promising results from aprospective trial, suggest siltuximab is a good option for CRS management. By directly targeting IL-6,siltuximab may accelerate recovery, and these preliminary data support the need for a prospective,randomized trial to evaluate its superiority for CRS response and time to resolution."

CAR T-Cell Therapy • Cytokine release syndrome • Hematological Malignancies • Inflammation

Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease (ASH 2025) - P2 | "While CRP reduction is observed quickly across all groups, significant reduction only occurred in patientswho would go on to respond to siltuximab, and maintaining low CRP levels across treatment cycles, asobserved from Cycle 2 and onwards, is associated with sustained CR. This suggests that CRP levels do notcome down as substantially and rebound in non-responders over time and underscores the importanceof continued IL-6 pathway suppression to maintain disease control in iMCD.This study reveals a highly dynamic relationship between maximal CRP reduction and both time andclinical response, suggesting that initial rapid suppression combined with sustained reduction areassociated with the best outcomes."

Clinical • Inflammation • Rare Diseases • CRP • IL6

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease (ASH 2025) - P2 | "Although siltuximab has been approved in manycountries, this first IL-6 blocking antibody only revealed a beneficial effect for 34% of patients with iMCD.To explore more effective therapy, a novel IL-6R antagonizing antibody (VDJ-001) with high-affinity andpotent activities has been assessed for safety and efficacy in this open-label phase II trial.A total of 25 Chinese iMCD patients with active disease were enrolled in this open-label, multi-center,dose-escalation and regimen study from April 2022 to September 2024; and their treatment responsesand safety profiles after VDJ-001 treatment were monitored up to June 18th, 2025 (last follow-up date)...The PK analysis indicated a different Cminprofile between two doses, [i.e., the median (range) of Cmin by Cycle 4 was 3.04 μg/mL(undetectable~14.4) for 4mg/kg group and 9.66 μg/mL (5.05~16.7) for 6mg/kg group respectively,] andonly 6 mg/kg dose met/exceeded the steady-state requirement of minimal concentration (Cmin)..."

Clinical • P2 data • Dyslipidemia • Eosinophilia • Hematological Disorders • Hypertriglyceridemia • Infectious Disease • Neutropenia • Novel Coronavirus Disease • Rare Diseases • IL6R

Increased type I interferon signaling is a hallmark of idiopathic multicentric castleman disease (ASH 2025) - "While there is an FDA-approved anti-interleukin-6 (IL-6) therapy, siltuximab, whichis effective in 34-50% of iMCD patients, disease etiology and pathophysiology remains largely unknown.While mTOR inhibition with sirolimus is effective in a subset of patients, the cell types and immunesignaling pathways dysregulated in iMCD are poorly understood. Together,our spatial transcriptomics data indicate that IFN-I is significantly upregulated specifically in germinalcenter regions of iMCD lymph nodes.These data demonstrate that IFN-I signaling is increased in the lymph nodes of iMCD patients acrossmultiple cell types, likely in the germinal center. Since IFN-I can lead to mTOR activation through PI3Ksignaling, it is possible that elevated IFN-I contributes to the elevated mTOR signature observed in iMCD.Given that IFN-I is significantly elevated in both circulation and LNs of iMCD patients, targeting INF-alphawith Anifrolumab may be a potential therapy for treatment refractory..."

Clinical • Epstein-Barr Virus Infections • Inflammation • Rare Diseases • CD4 • CD8 • IFNA1 • IL6 • STAT1

Early recognition and optimized management of tafro syndrome: A 10-year experience from a single center in China (ASH 2025) - "Among patients receiving active treatment, glucocorticoid treatment alone and CTD(combined cyclophosphamide, thalidomide, and dexamethasone) regimen were almost universallyunsuccessful. In contrast, IL-6 inhibitor-based therapies (tocilizumab or siltuximab combined with CTD ±rituximab) achieved a CR rate of 100% (4/4), with sustained remission maintained through subsequentmaintenance therapy with IL-6 inhibitors or thalidomide... Based on our 10-year single-center experience, we emphasize two critical recommendations.First, combining the classical "TAF" triad with specific morphological abnormalities observed in bonemarrow megakaryocytes and peripheral blood cytomorphology constitutes an effective early diagnostictool for TAFRO syndrome. Second, we strongly advocate for an IL-6 inhibitor-containing R-CTD regimenas the standard first-line therapy due to its substantial impact on improving patient outcomes.Nonetheless, further validation through broader..."

Clinical • Hematological Disorders • Infectious Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Thrombocytopenia

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients (ASH 2025) - "The most common CAR T-cell products wereaxicabtagene ciloleucel (n = 31, 25%), brexucabtagene autoleucel (n = 26, 21%), and tisagenlecleucel (n =21, 17%)...Nearly all (n = 123; 99%) patients received concurrent dexamethasone (dex) with a median totaldose of 234 mg (range, 30-690)...Sixteen patients (13%)received additional therapies, including ruxolitinib (n = 1), siltuximab (n = 3), cetuximab (n = 1), intrathecalchemotherapy (n = 11), and dasatinib (n = 1)...Higher dex doses remainedassociated with shorter time to ICANS resolution, highlighting that corticosteroids remain thecornerstone of treating refractory ICANS. More effective strategies for anakinra-refractory ICANS arecritically needed."

CAR T-Cell Therapy • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results (ASH 2025) - P1, P1/2 | "CAR naïve patients received fludarabine 75mg/m2 and cyclophosphamide900mg/m2 for lymphodepletion (LD), whereas CAR pretreated patients received intensified LD withfludarabine 120mg/m2 and cyclophosphamide 1200mg/m2.During the expansion phase, eligibility was broadened to include an isolated CNS (iCNS) disease cohortand to test the efficacy of siltuximab as first line therapy for cytokine release syndrome (CRS)...Seven (25%) required both tocilizumab andsteroids... The extended experience with this construct highlights safety and efficacy warrantingfurther exploration of these properties in future constructs. Non-response occurred only in patients withnon-CNS EMD, highlighting ongoing challenges in targeting EMD. Institutional efforts have shifted to test abicistronic CD19.28ζ /CD22.BBζ construct with initial results demonstrating enhanced efficacy, CD22targeting, and persistence (NCT05442515)."

CAR T-Cell Therapy • Clinical • P1 data • Bone Marrow Transplantation • Burkitt Lymphoma • CNS Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Rare Diseases • CD22

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) (ASH 2025) - P1/2 | "Sixteen pts (46%) were previously treated with blinatumomaband 13 pts (37%) with inotuzumab...CRS management includedtocilizumab (70%), siltuximab (10%), corticosteroids (40%), tocilizumab plus corticosteroids (37%), andanakinra (7%)...Seven pts received supportive measures for ICANS,including dexamethasone (5 pts, 71%) and anakinra (3 pts, 43%)... Phase 1 results with long follow-up suggest rapcabtagene autoleucel is active with highcellular expansion, durable efficacy for DL2–DL4, and a manageable safety profile in adult pts with r/r B-ALL. DL3—at which 92% of pts achieved BOR of CR/CRi by 3 mo, with median DOR not reached after 22mo median follow-up—exhibited an acceptable balance of safety, efficacy, and cellular expansion."

Clinical • P1 data • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Neutropenia • Rare Diseases

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab (ASH 2025) - "We assesseddisease severity with a modified CHA score [C-reactive protein (CRP), hemoglobin, albumin] within 90days of diagnosis.Regimens were defined as treatments started within two weeks of each other and categorized into thefollowing six groups: siltuximab±corticosteroids (CS), tocilizumab±CS, immunomodulator(s)±CS, anti-IL-6+immunomodulator±CS, chemotherapy±other treatments, or CS monotherapy. Immunomodulatorsincluded sirolimus, rituximab, ruxolitinib, anakinra, lenalidomide, eculizumab, plasmapheresis, andothers...In the largest pediatric iMCD analysis to date, we found more severe disease with higher CHA scores andmore TAFRO cases than in adults. We observed high response rates to siltuximab in children, which weresimilar to those in adults. Since the phase 2 siltuximab trial excluded children and had few TAFRO cases,these results are reassuring with no new safety concerns."

Clinical • Cardiovascular • Diabetes • Fibrosis • Hematological Disorders • Hypertension • Immunology • Inflammation • Nephrology • Otorhinolaryngology • Pediatrics • Rare Diseases • Renal Disease • Thrombocytopenia

MEFV E148Q-P369S-R408Q germ line variant identified from the adolescent imcd-tafro family conferred severe disease manifestations in a cohort of 37 patients with castleman disease (ASH 2025) - "The siltuximab-based anti-IL-6 regimen demonstrated promising clinicalefficacy, with the patient maintaining complete remission for 36 months of follow-up at the time ofAbstract preparation.Using WES, we identified Mediterranean fever (MEFV) E148Q-P369S-R408Q germ line variant in thepatient, inherited from his asymptomatic parents. Our study adds to the very limited literature by describing the genomic characteristics of anadolescent TAFRO and the high responsiveness to anti-IL-6 based therapy. MEFV E148Q-P369S-R408Qgerm line variant was identified and appeared to be potent in promoting inflammation induced by LPS,which was partly abrogated by colchicine in vitro. ScRNA-seq revealed that MEFV-enriched CD16+monocytes interacted with naïve B/memory B cells, contributing to IL-6 pathway activation."

Clinical • Hematological Disorders • Inflammation • Myelofibrosis • Rare Diseases • Thrombocytopenia • IL1B

Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort (ASH 2025) - "Currently, 21 patients are on treatment with siltuximab (90,4%), 1 with sirolimus (4.8%)and 1 with tocilizumab (4.8%). Theprevalence of iMCD in Spain is very low and similar to that reported from other geographical areas.Hypertension and autoimmune disorders were the most common comorbidities. IL-6 blockade iscurrently the most common therapeutic approach and the majority of patients have a favorableresponse to standard therapy."

Clinical • Benign Prostatic Hyperplasia • Cardiovascular • Cervical Cancer • Gynecology • Hypertension • Immunology • Infectious Disease • Rare Diseases • Thrombosis

Comprehensive analysis of subtype-specific outcomes and management in castleman disease: A 20-year cohort Study (ASH 2025) - "Those treated with rituximab orglucocorticoid monotherapy required subsequent therapy in 50% and 43%, respectively.Within iMCD subtypes (TAFRO (n=16), IPL (n=9), and NOS (n=26)), the 5-year OS was 80.4%, 100%, and91.0%, respectively, without significant differences among the subtypes. This extensive, retrospective cohort study supports the clinical relevance of updated CDsubtype classification. As the present study spans two decades, it reflects evolving diagnostic criteria andtherapeutic standards, including the 2014 FDA approval of siltuximab, the iMCD consensus criteria in2017, with the addition of OligoCD and iIPL. The findings confirm the aggressive clinical nature of iMCDand suggest that OligoCD demonstrated intermediate features between UCD and iMCD, though closer toUCD in outcome."

Epstein-Barr Virus Infections • Fibrosis • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Nephrology • Rare Diseases • Renal Disease • Thrombocytopenia • IL6

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians (ASH 2025) - "While theproportion of pts receiving glofitamab was similar between the older and younger cohorts (45.1% vs43.6%), a slightly higher proportion of the older cohort received mosunetuzumab (39.2% vs 27.7%) and alower proportion received epcoritamab (15.7% vs 25.2%) (p=0.2)...The older cohort received more steroids (p=0.6),tocilizumab (p=1.0), and siltuximab (p=0.2) for CRS management...In pts aged ≥80 years with R/R LBCL treated with BsAb, PFS and LSS were comparable to younger pts.Although OS was numerically shorter in the older cohort, this was not statistically significant, likely due toshort follow-up. No factors, including age, were prognostic of PFS or OS. Safety outcomes, including CRS,NT, and infection rates, were similar across age groups, except for a higher incidence of grade ≥3 CRS inthe older cohort."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Atypical neurotoxicity in CAR-T cell therapy: A retrospective analysis of unusual icans presentations and their clinical implications (ASH 2025) - "Atypical ICANSoccurred in 16 patients (4.5%) with a median age of 64.3 years (SD ±11) and a male predominance (56%).The majority had NHL (75%) and received Axi-cel (69%) or Cilta-cel (25%)...Additional agents used includedtocilizumab, siltuximab, anakinra, intravenous immunoglobulin (IVIG), and anti-thymocyte globulin...Atypical ICANS occurred in 4.5% of CAR-T–treated patients with NHL or MM and was associated withdelayed diagnosis, diverse neurologic symptoms, diagnostic challenges, and significant morbidity (69%with persistent deficits) and mortality (19%). Early recognition and immunosuppressive treatment mayimprove outcomes. Despite study limitations such as retrospective design and small sample size, thesefindings emphasize the need for improved diagnostic framework and heightened clinical awareness."

CAR T-Cell Therapy • Retrospective data • Cardiovascular • CNS Disorders • Epilepsy • Epstein-Barr Virus Infections • Hematological Malignancies • Ischemic stroke • Lymphoma • Movement Disorders • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Parkinson's Disease

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor (ASH 2025) - "We sought to definethis cohort of responders to a second IL-6 inhibitor by comparing them to patients refractory to bothsiltuximab and tocilizumab.MethodsWe utilized two registries: ACCELERATE, the largest international registry of iMCD patients, that leveragesan expert panel to confirm every patient diagnosis, and Peking Union Medical College Hospital, thelargest single-center registry of Chinese iMCD patients...Six of 9 patientsreceived corticosteroids with the first IL-6 inhibitor, and 3 received other medications(hydroxychloroquine, rituximab, sirolimus, and chemotherapy)...Despite limited numbers, we observed that responders to a second IL-6inhibitor were more likely to have the IPL subtype. In a disease with few alternatives, this cohort suggestsan unexpected therapeutic benefit to trialing a second IL-6 inhibitor following an initial nonresponse."

Clinical • Fibrosis • Hematological Disorders • Immunology • Inflammation • Nephrology • Rare Diseases • Renal Disease • Thrombocytopenia • CRP

Direct IL-6 sequestration with siltuximab rescues CAR T-cell proliferation from inflammatory suppression: A longitudinal multi-omic analysis supporting a paradigm shift in CRS management (ASH 2025) - "The standard-of-care, tocilizumab, paradoxically elevates circulating IL-6, posing theoreticalrisks. Our data provide the first clinical evidence for a critical inflammatory threshold beyondwhich the cytokine storm actively suppresses CAR T-cell proliferation. By rapidly and directly neutralizingIL-6, siltuximab not only provides superior control of fulminant CRS but may also be crucial for preservingCAR T-cell functional fitness. This study suggests that the choice of anti-IL-6 agent is not merely a toxicitymanagement decision but a key determinant of cellular therapy efficacy."

CAR T-Cell Therapy • Omic analysis • Hematological Malignancies • IL6 • IL6R

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results (ASH 2025) - "CD19.CART product was axicabtageneciloleucel (4 pts), tisagenlecleucel (4), and lisocabtagene maraleucel (2). Siltux was safe as ppx prior to CD19.CART. No gr > 3 CRS occurred and only 1 pt developed gr> 3 ICANS which fully resolved. CD19.CART ORR and CR rate were excellent and responses were durable.In addition, siltux ppx resulted in a favorable phenotypic and functional differentiation of CAR+ T-cellspost-infusion and reduction in cytokines typically associated with CRS/ICANS."

CAR T-Cell Therapy • Clinical • Immunomodulating • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • B3GAT1 • CCL3 • CD8 • CRP • CXCL10 • GZMB • IFNG • IL15 • IL2 • IL6R • IL7 • TNFA

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model. (PubMed, Ann Hematol) - "Using the generalized linear mixed model in order to provide an indirect comparison of odds to achieve the 2yPFS end-point, the reported OR is 0,358, 95% CI (0,147-0,873) and p = 0,027 favoring siltuximab over rituximab-based regimens (RBR). This is the major finding of our study and to our knowledge is the first time that in a big cohort of patients siltuximab is proved more effective compared to RBR."

Journal • Monotherapy • Rare Diseases